Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in April 2010, to inform of new safety information and advice.
| Date issued | Product | Safety information |
|---|---|---|
| 29 April 2010 | Avastin (bevacizumab) (224Kb) |
Hypersensitivity and infusion reactions. |
| 28 April 2010 | Exelon transdermal patch (rivastigmine) (251Kb) |
Medication errors. |
| 22 April 2010 | Fabrazyme (agalsidase beta) (276Kb) |
Supply shortages and treatment recommendations. |
| 22 April 2010 | Cerezyme (imiglucerase) (211Kb) |
Supply shortages and treatment recommendations. |
| 20 April 2010 | Vectibix (panitumumab) (466Kb) |
Serious hypersensitivity reactions. |
| 15 April 2010 | Kepivance (palifermin) (741Kb) |
Restricted indication: now for patients who receive both radiotherapy and chemotherapy before autologous stem-cell transplantation. |
